ID   MCF7/LCC9
AC   CVCL_DP52
SY   MCF-7/LCC9; LCC9
DR   BTO; BTO:0005970
DR   cancercelllines; CVCL_DP52
DR   Wikidata; Q54904470
RX   PubMed=9270017;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:31638; Fulvestrant (ICI 182780).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_DP50 ! MCF7/LCC1
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 13-07-16; Last updated: 05-10-23; Version: 13
//
RX   PubMed=9270017;
RA   Brunner N., Boysen B., Jirus S., Skaar T.C., Holst-Hansen C.,
RA   Lippman J., Frandsen T.L., Spang-Thomsen M., Fuqua S.A.W., Clarke R.;
RT   "MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired
RT   resistance to the steroidal antiestrogen ICI 182,780 confers an early
RT   cross-resistance to the nonsteroidal antiestrogen tamoxifen.";
RL   Cancer Res. 57:3486-3493(1997).
//